

- C1  
CONT  
SUB  
D1  
CONT.
- i. incubating a suspension of said precursor cells in a proliferating medium which includes basic fibroblast growth factor (bFGF) to form proliferated precursor cells; and
  - b. differentiating said precursor cells, said step of differentiating comprising:
    - i. incubating said precursor cells in an incubation vessel which contains differentiation medium in a manner effective to form a reaggregation of differentiated dopaminergic neuron cells that is not adhered to any surface of the incubation vessel, wherein the differentiation medium includes ascorbic acid;

wherein said precursor cells comprise fetal central nervous system cells.

- C2
20. A method of treating a patient for Parkinson's disease, said method comprising administering cells produced according to the method of claim 1 to the patient to treat the patient for Parkinson's disease.

- C3
23. The method of claim 22 wherein introducing a therapeutically effective amount further comprises administering  $1-4 \times 10^6$  dopaminergic neurons, wherein administering further comprises loading said cells into a syringe and injecting them within the parenchyma of the patient's brain.

24. An assay for evaluating the effect of substances on differentiated neuronal cells, comprising:
- A. culturing differentiated neuronal cells, said step of culturing comprising:
    - i. proliferating neuronal precursor cells, said step of proliferating comprising:

C3  
cont

- a. incubating said neuronal precursor cells in proliferating medium which includes basic fibroblast growth factor (bFGF); and
- ii. differentiating said neuronal precursor cells, said step of differentiating comprising:
  - aa. incubating said precursor cells in an incubation vessel which contains differentiation medium in a manner effective to form a reaggregation of differentiated cells that is not adhered to any surface of the incubation vessel, wherein said differentiating medium includes ascorbic acid,
- B. exposing said differentiated neuronal cells to the substance; and
- C. observing the effect of the substance on said differentiated neuronal cells.

---

Please introduce new claims 25-27 as follows.

25. The method of claim 1, wherein the precursor cells are obtained during a sensitive period.

26. The method of claim 25, wherein the precursor cells comprise human fetal cells obtained between about embryonic week 5 and about embryonic week 8.

27. The method of claim 25, wherein the precursor cells further comprise rat fetal cells obtained between about embryonic day 10 and about embryonic day 12.

---

C4  
Sub  
F2